In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells
Marco Donia(University of Copenhagen), Ferdinando Nicoletti(University of Catania), James A. McCubrey(East Carolina University), Djordje Miljković(University of Belgrade), Sanja Mijatović(University of Belgrade), Paolo Fagone(University of Catania), Marija Mojić(Northwell Health), S Caponnetto(University of Catania), Yousef Al‐Abed(Feinstein Institute for Medical Research), Danijela Maksimović‐Ivanić(Institute for Biological Research “Siniša Stanković”), Stanislava Stošić‐Grujičić(Institute for Biological Research “Siniša Stanković”), Gordana Timotijević(Northwell Health)
Cited by 40
Related Papers
Natural products in drug discovery: advances and opportunities
|Nature Reviews Drug Discovery|2021|5.2k
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
|Oncotarget|2011|579
GSK-3 as potential target for therapeutic intervention in cancer
|Oncotarget|2014|508
The neuropathic pain: An overview of the current treatment and future therapeutic approaches
|International Journal of Immunopathology and Pharmacology|2019|495